Two-headed PROTAC: an Effective New Tool for Targeted Protein Degradation

Overview

Journal Chembiochem

Specialty Biochemistry

Date 2010 Jun 24

PMID 20572252

Citations 15

Authors

Kedra Cyrus

Marie Wehenkel

Eun-Young Choi

Hollie Swanson

Kyung-Bo Kim

Affiliations

Soon will be listed here.

Citing Articles

Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance.

Peng R, Liu X, Chen C, Guo R, Min J RSC Med Chem. 2025; .

PMID: 39823043 PMC: 11734508. DOI: 10.1039/d4md00961d.

Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.

Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.

PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies.

Peng X, Hu Z, Zeng L, Zhang M, Xu C, Lu B Acta Pharm Sin B. 2024; 14(2):533-578.

PMID: 38322348 PMC: 10840439. DOI: 10.1016/j.apsb.2023.09.003.

Targeted Protein Degradation: Clinical Advances in the Field of Oncology.

Salama A, Trkulja M, Casanova E, Uras I Int J Mol Sci. 2022; 23(23).

PMID: 36499765 PMC: 9741350. DOI: 10.3390/ijms232315440.

Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape.

Francois-Moutal L, Scott D, Khanna M RSC Chem Biol. 2021; 2(4):1158-1166.

PMID: 34458829 PMC: 8341936. DOI: 10.1039/d1cb00110h.

References

Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim K, Crews C, Deshaies R . Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene. 2008; 27(57):7201-11. PMC: 5573236. DOI: 10.1038/onc.2008.320. View

Zhang D, Baek S, Ho A, Lee H, Jeong Y, Kim K . Targeted degradation of proteins by small molecules: a novel tool for functional proteomics. Comb Chem High Throughput Screen. 2004; 7(7):689-97. DOI: 10.2174/1386207043328364. View

Puppala D, Lee H, Kim K, Swanson H . Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention. Mol Pharmacol. 2008; 73(4):1064-71. DOI: 10.1124/mol.107.040840. View

Zheng F, Kuduk S, Chiosis G, Munster P, Sepp-Lorenzino L, Danishefsky S . Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000; 60(8):2090-4. View

Kuduk S, Harris T, Zheng F, Sepp-Lorenzino L, Ouerfelli Q, Rosen N . Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett. 2000; 10(11):1303-6. DOI: 10.1016/s0960-894x(00)00208-0. View

Sin N, Kim K, Elofsson M, Meng L, Auth H, Kwok B . Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett. 1999; 9(15):2283-8. DOI: 10.1016/s0960-894x(99)00376-5. View

Deshaies R . SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999; 15:435-67. DOI: 10.1146/annurev.cellbio.15.1.435. View

Itoh Y, Ishikawa M, Naito M, Hashimoto Y . Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc. 2010; 132(16):5820-6. DOI: 10.1021/ja100691p. View

Kudrin A . Trace elements in regulation of NF-kappaB activity. J Trace Elem Med Biol. 2000; 14(3):129-42. DOI: 10.1016/s0946-672x(00)80001-2. View

10.

Sakamoto K, Kim K, Verma R, Ransick A, Stein B, Crews C . Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteomics. 2003; 2(12):1350-8. DOI: 10.1074/mcp.T300009-MCP200. View

11.

Zhang S, Qin C, Safe S . Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect. 2003; 111(16):1877-82. PMC: 1241760. DOI: 10.1289/ehp.6322. View

12.

Hershko A, Ciechanover A . The ubiquitin system. Annu Rev Biochem. 1998; 67:425-79. DOI: 10.1146/annurev.biochem.67.1.425. View

13.

Lee H, Puppala D, Choi E, Swanson H, Kim K . Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool. Chembiochem. 2007; 8(17):2058-62. DOI: 10.1002/cbic.200700438. View

14.

Verma R, Peters N, DOnofrio M, Tochtrop G, Sakamoto K, Varadan R . Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science. 2004; 306(5693):117-20. DOI: 10.1126/science.1100946. View

15.

Schneekloth Jr J, Fonseca F, Koldobskiy M, Mandal A, Deshaies R, Sakamoto K . Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc. 2004; 126(12):3748-54. DOI: 10.1021/ja039025z. View

16.

Schreiber S . Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg Med Chem. 1998; 6(8):1127-52. DOI: 10.1016/s0968-0896(98)00126-6. View

17.

Zhang D, Baek S, Ho A, Kim K . Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorg Med Chem Lett. 2004; 14(3):645-8. DOI: 10.1016/j.bmcl.2003.11.042. View

18.

Skowyra D, Craig K, Tyers M, Elledge S, Harper J . F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell. 1997; 91(2):209-19. DOI: 10.1016/s0092-8674(00)80403-1. View

19.

Strausberg R, Schreiber S . From knowing to controlling: a path from genomics to drugs using small molecule probes. Science. 2003; 300(5617):294-5. DOI: 10.1126/science.1083395. View

20.

Sakamoto K, Kim K, Kumagai A, Mercurio F, Crews C, Deshaies R . Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A. 2001; 98(15):8554-9. PMC: 37474. DOI: 10.1073/pnas.141230798. View